BioMarin to acquire Amicus Therapeutics for $4.8 billion ○
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in rare metabolic diseases.